{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","statisticalComment":"Cochran-Mantel-Haenszel (CMH) adjusted for geographic region and etiology liver disease","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.6","upperLimit":"10.7","value":"7.1"},{"groupId":"OG001","lowerLimit":"0.2","upperLimit":"2.5","value":"0.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"283"},{"groupId":"OG001","value":"282"}],"units":"Participants"}],"description":"ORR was defined, using RECIST v1.1 criteria, as the percentage of participants who achieved a best overall response of CR or PR. CR was defined as the disappearance of all lesions and any intratumor arterial enhancement in target lesions, the normalization of the tumor marker level and all lymph nodes short axis reduced to \\<10 mm. PR was defined as ≥30% decrease in the SOD of target lesions, including the short axes of any target lymph nodes, taking as reference the baseline SOD of target lesions, no new lesions and stable nontarget lesions. Percentage of participants was calculated as: (number of participants with CR or PR / number of participants randomized) \\* 100.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"NUMBER","populationDescription":"ITT Population: All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline to the date of first evidence of confirmed CR or PR (up to 37 months)","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]","type":"SECONDARY","unitOfMeasure":"percentage of participants"}